Wang et al. [128] prepared a series of 3-O- and 9-O-derivatives of berberine with the hope to find a better cancer immunotherapeutic agent via targeting indoleamine 2,3-dioxygenase 1 (IDO1). This evidence concerns the gene IDO1 and cancer.